Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients

Pharmacotherapy

Volumn 28, Issue 5 PART 1, 2008, Pages 553-561

  Miller, Amy E ^a   Hansen, Laura B ^b   Saseen, Joseph J ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Dyslipidemia; Indigent care; LDL; Low density lipoprotein cholesterol; Pharmacist managed; Statins; Therapeutic conversion

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALGORITHM; AMBULATORY CARE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DRUG FORMULARY; DRUG SUBSTITUTION; DYSLIPIDEMIA; FAMILY MEDICINE; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACIST; PROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; ANTILIPEMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; COLORADO; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHARMACISTS; POVERTY; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES;

EID: 42949138132     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.5.553     Document Type: Article

References (40)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
3. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
4. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
6. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial - lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
7. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation 2004;110:227-39.
9. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-9.
10. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
11. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
12. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
13. Hilleman DE, Wurdeman RL, Lenz TL. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy 2001;21:410-15.
14. Raal FJ. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J S Afr 2004;15:118-23.
15. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract 2007;61:15-23.
16. Rindone JP, Arriola G. Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost. Clin Ther 1998;20:340-6.
17. Patel RJ, Gray DR, Pierce R, Jafari M. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs medical center. Am J Manag Care 1999;5:465-74.
18. Fugit RV, Resch ND. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am J Health Syst Pharm 2000;57:1703-8.
19. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. Am J Health Syst Pharm 1995;52:1078-82.
20. Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy 2001;21:1130-9.
21. Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to- simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm 2001;58:1734-9.
22. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
23. Valuck RJ, Williams SA, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003;25:2936-57.
24. Clearfield MB. Underidentification and undertreatment of dyslipidemia. J Am Osteopath Assoc 2003;103:S5-8.
25. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
26. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60.
27. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.
28. Saseen J, Tweed E, Crawford P. Clinical inquiries. What are effective medication combinations for dyslipidemia? J Fam Pract 2006;55:70-2.
29. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041-53.
30. Preacher KJ. Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence. Last updated January 18, 2008. Available from www.psych.ku.edu/preacher/chisq/chisq. htm. Accessed April 20, 2007.
31. Collins C, Kramer A, O'Day ME, Low MB. Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center. Am J Health Syst Pharm 2006;63:1723-7.
32. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. J Manag Care Pharm 2005;11:763-71.
33. Straka RJ, Taheri R, Cooper SL, Smith JC. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy 2005;25:360-71.
34. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm 2003;9:269-73.
35. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ, Eastham JH, Sandoval R. Development of a pharmacist-managed lipid clinic. Ann Pharmacother 2002;36:892-904.
36. Nair KV, Saseen JJ. Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality. Ann Pharmacother 2006;40:124-7.
37. Leiter LA, Rosenson RS, Stein E, et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007;194:e154-64.
38. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
39. AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) package insert, Wilmington, DE; January 2007.
40. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(suppl 1):S4-41.